Satish Shanbhag1,2, Nina Wagner-Johnston1, Richard F Ambinder1, Richard J Jones3. 1. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Room 244, Bunting-Blaustein Cancer Research Bldg., 1650 Orleans Street, Baltimore, MD, 21231, USA. 2. Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Room 244, Bunting-Blaustein Cancer Research Bldg., 1650 Orleans Street, Baltimore, MD, 21231, USA. rjjones@jhmi.edu.
Abstract
PURPOSE OF REVIEW: A multitude of new drug and cell therapy approvals for lymphoma has prompted questions about the role of allogeneic blood or marrow transplantation (allo-BMT). We sought to review the latest evidence examining the role of allo-BMT for lymphoma in this evolving landscape. RECENT FINDINGS: Despite several new drug classes, there remains a large unmet need, particularly in hard to treat subtypes of lymphoma and for patients with relapsed/refractory disease. Allo-BMT can provide an opportunity for cure due to a potent graft vs lymphoma effect in high-risk relapse/refractory follicular lymphoma, mantle cell lymphoma, and aggressive T cell lymphomas. Chimeric antigen receptor T cell therapy and checkpoint blockers have improved outcomes for patients with relapsed /aggressive B cell lymphomas and Hodgkin lymphoma respectively; the role of allo-BMT consolidation in the treatment algorithm for responders to these therapies is an evolving topic. Expanded donor availability including haploidentical relatives has improved access to allo-BMT. Non-myeloablative conditioning regimens and post-transplant cyclophosphamide prophylaxis have improved early transplant-related morbidity and rates of graft versus host disease and translated into long-term survival for patients with lymphoid malignancies. Patient selection remains key, but allo-BMT remains the only modality able to deliver durable long-term remissions across different types of lymphoma.
PURPOSE OF REVIEW: A multitude of new drug and cell therapy approvals for lymphoma has prompted questions about the role of allogeneic blood or marrow transplantation (allo-BMT). We sought to review the latest evidence examining the role of allo-BMT for lymphoma in this evolving landscape. RECENT FINDINGS: Despite several new drug classes, there remains a large unmet need, particularly in hard to treat subtypes of lymphoma and for patients with relapsed/refractory disease. Allo-BMT can provide an opportunity for cure due to a potent graft vs lymphoma effect in high-risk relapse/refractory follicular lymphoma, mantle cell lymphoma, and aggressive T cell lymphomas. Chimeric antigen receptor T cell therapy and checkpoint blockers have improved outcomes for patients with relapsed /aggressive B cell lymphomas and Hodgkin lymphoma respectively; the role of allo-BMT consolidation in the treatment algorithm for responders to these therapies is an evolving topic. Expanded donor availability including haploidentical relatives has improved access to allo-BMT. Non-myeloablative conditioning regimens and post-transplant cyclophosphamide prophylaxis have improved early transplant-related morbidity and rates of graft versus host disease and translated into long-term survival for patients with lymphoid malignancies. Patient selection remains key, but allo-BMT remains the only modality able to deliver durable long-term remissions across different types of lymphoma.
Entities:
Keywords:
Allogeneic transplant; Diffuse large B cell lymphoma; Graft vs host disease; Graft-versus-lymphoma effect; Hodgkin lymphoma; Lymphoma; Mantle cell lymphoma; Non-Hodgkin lymphoma
Authors: Ivan Aksentijevich; Richard J Jones; Richard F Ambinder; Elizabeth Garrett-Mayer; Ian W Flinn Journal: Biol Blood Marrow Transplant Date: 2006-09 Impact factor: 5.742
Authors: A D Schimmer; S Jamal; H Messner; A Keating; J Meharchand; L Huebsch; I Walker; A Benger; S Gluck; A Smith Journal: Bone Marrow Transplant Date: 2000-10 Impact factor: 5.483
Authors: R Chopra; A H Goldstone; R Pearce; T Philip; F Petersen; F Appelbaum; E De Vol; P Ernst Journal: J Clin Oncol Date: 1992-11 Impact factor: 44.544
Authors: Lauri M Burroughs; Paul V O'Donnell; Brenda M Sandmaier; Barry E Storer; Leo Luznik; Heather J Symons; Richard J Jones; Richard F Ambinder; Michael B Maris; Karl G Blume; Dietger W Niederwieser; Benedetto Bruno; Richard T Maziarz; Michael A Pulsipher; Finn B Petersen; Rainer Storb; Ephraim J Fuchs; David G Maloney Journal: Biol Blood Marrow Transplant Date: 2008-11 Impact factor: 5.742
Authors: Abdulwahab J Al-Tourah; Karamjit K Gill; Mukesh Chhanabhai; Paul J Hoskins; Richard J Klasa; Kerry J Savage; Laurie H Sehn; Tamara N Shenkier; Randy D Gascoyne; Joseph M Connors Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544
Authors: K J Thomson; K S Peggs; P Smith; J Cavet; A Hunter; A Parker; R Pettengell; D Milligan; E C Morris; A H Goldstone; D C Linch; S Mackinnon Journal: Bone Marrow Transplant Date: 2008-01-14 Impact factor: 5.483
Authors: Anna Sureda; Stephen Robinson; Carmen Canals; Angelo M Carella; Marc A Boogaerts; Dolores Caballero; Ann E Hunter; Lothar Kanz; Shimon Slavin; Jan J Cornelissen; Martin Gramatzki; Dietger Niederwieser; Nigel H Russell; Norbert Schmitz Journal: J Clin Oncol Date: 2007-12-17 Impact factor: 44.544
Authors: Paolo Corradini; Anna Dodero; Francesco Zallio; Daniele Caracciolo; Marco Casini; Marco Bregni; Franco Narni; Francesca Patriarca; Mario Boccadoro; Fabio Benedetti; A Rambaldi; Alessandro M Gianni; Corrado Tarella Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Sabine Kürzel; André-René Blaudszun; Lilly Stahl; Stephan Fricke; Mathias Hänel; Regina Herbst; Frank Kroschinsky; Josef Birkmann; Annette Hänel; Kerstin Schaefer-Eckart; Gerhard Ehninger; Friedrich Fiedler; Martin Bornhäuser Journal: J Cancer Res Clin Oncol Date: 2021-06-26 Impact factor: 4.322